AmyloSENS Archives - SENS Research Foundation

Get the Message: mRNA to Target Intracellular Aggregates

July 8, 2024July 6, 2024 by Michael Rae

Several pharma companies are currently running clinical trials on damage-repair therapies targeting damaged forms of the protein tau to combat Alzheimer’s disease. But these AmyloSENS therapies only reach tau in the fluid outside of neurons, when what we need is to clear damaged tau inside of them. Fortunately, researchers are beginning to use mRNA — the same revolutionary biotechnology platform of the best COVID vaccines — to develop new LysoSENS therapies to do just that.

SENSible Question: Beta-Amyloid and Dementia: “Never” is a Very Long Time

April 29, 2024April 26, 2024 by Michael Rae

An article criticizes the diagnosis of Alzheimer’s in its earliest stages based on the presence of beta-amyloid or other aging damage in the brain and read this post to understand why this critique may be unfounded.

Repairing the Damage to Shake Off Parkinson’s

April 24, 2024April 7, 2024 by Michael Rae

How SENS “damage-repair” longevity therapeutics can prevent and reverse the second most common neurodegenerative disease: neurodegenerative aging of the Parkinson’s type.

AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

March 26, 2024February 8, 2024 by Michael Rae

The Phase III trials for AmyloSENS rejuvenation biotechnologies lecanemab/Leqembi® and donanemab showed that they are most effective when given to people with less of other kinds of cellular and molecular aging damage in their brains. New data illustrates that fact even more powerfully and gives us a foreshadowing of what’s possible if we make best use of these and forthcoming damage-repair longevity therapeutics.

New Molecules on the Frontline Battling Brain Infections and Harmful PlaqueAmylo

March 29, 2024September 5, 2023 by SRF

Stanford University Principal Investigator: Annelise E. BarronResearch Team: Kristian Sørensen, Jennifer Lin, Josefine Eilsø Nielsen, and John Fortkort The aging brain is vulnerable to invasion by infectious microbes, and there is compelling evidence that some of these pathogens drive neurodegenerative aging of the Alzheimer’s type (AD). One of the ways these microbes promote the disease …

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

February 13, 2024August 2, 2023 by Michael Rae

TTR cardiac amyloid contributes to heart failure and appears to limit the lives of the longest-lived humans. One AmyloSENS antibody shows high promise to remove this amyloid and restore function in the aging heart in an early-stage clinical trial. A second such antibody is coming close behind it, and a tiny number of people’s immune systems appear to generate such antibodies on their own.

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

June 7, 2024June 5, 2023 by Michael Rae

Another clinical trial has now proven that a second AmyloSENS rejuvenation biotechnology that clears beta-amyloid aggregates from the brain also slows down the slide into dementia in people in the early stages of Alzheimer’s disease, but this development is only the beginning.

SENSible Question: Is Targeting Beta-Amyloid Founded on Fraud?

February 28, 2023January 10, 2023 by Michael Rae

A supporter asks about the investigative report in Science magazine that suggests the critical study identifying beta-amyloid oligomers as the key actors in Alzheimer’s disease may have been based on fraudulent data.

EoY 2022-AmyloSENS

December 28, 2022December 23, 2022 by SRF

Week Seven of our 2022 End of Year Campaign features AmyloSENS (Removing Junk from Between Cells) – with a disease focus on Challenging Heart Disease. Also featuring videos from Life Noggin, AMA with Dr. Sudhir Paul and Michael Rae.

Does An Immune Role for Beta- Amyloid Create a Therapeutic Dilemma for SENS?

November 18, 2022September 8, 2022 by Michael Rae

Some scientists have reported that viruses, bacteria, and other pathogens may help drive Alzheimer’s and other neurodegenerative diseases, and that the body uses beta-amyloid protein to fight them off. That seems to imply that it’s a bad idea to remove Abeta from the brain. Here we explain how the SENS “damage-repair” strategy leaps over that therapeutic dilemma — just as it does with other kinds of aging damage.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Get the Message: mRNA to Target Intracellular Aggregates

SENSible Question: Beta-Amyloid and Dementia: “Never” is a Very Long Time

Repairing the Damage to Shake Off Parkinson’s

AmyloSENS Therapies for Alzheimer’s: The Marathon and the Decathlon

New Molecules on the Frontline Battling Brain Infections and Harmful PlaqueAmylo

Set My Heart Free: Two AmyloSENS Therapies Targeting Cardiac Amyloid in Clinical Trials

From Parachutes to Jetpacks: Clearing Brain Beta-Amyloid with Donanemab or Lecanemab Works, Though More Must be Done

SENSible Question: Is Targeting Beta-Amyloid Founded on Fraud?

EoY 2022-AmyloSENS

Does An Immune Role for Beta- Amyloid Create a Therapeutic Dilemma for SENS?

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

About Us

Our Research

Education Opportunities

Get Involved

Receive our NewslEtter

We respect your privacy. You can unsubscribe at any time.

Thank you for Subscribing to the SENS Research Foundation Newsletter.

You can also

or

You can